Although the contribution of ACE2 in the pathogenesis of COVID-19 is not known, yet it has been delineated that SARS-CoV infection downregulates ACE2 and worsens lung injury that is reversed by treatment with Angiotensin receptor blocker-mediated upregulation of ACE2 (Imai et al., 2005). The gene discussed is ACE2; the disease is COVID-19.